Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M5717 + pyronaridine for chemoprevention of P. falciparum malaria
NCT05974267Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of cabamiquine in Plasmodium falciparum malaria, sponsored by Merck KGaA. Started Nov 2023; status: completed.
02
Drugs
cabamiquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT05974267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05974267.